Economic appraisal of antidepressant pharmacotherapy: critical review of the literature and future directions
β Scribed by David A. Sclar; Tracy L. Skaer; Linda M. Robison; Julie K. Stowers
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 57 KB
- Volume
- 8
- Category
- Article
- ISSN
- 1091-4269
No coin nor oath required. For personal study only.
β¦ Synopsis
In the United States, an estimated $44 billion is expended annually for the treatment, morbidity, and mortality associated with depression. Domestic and international cost-containment initiatives are mandating a demonstration of value for money defined in terms of a measurable health and/or financial outcome, and, in the case of medicines, attributable to a given expenditure for a given pharmacotherapeutic option. Recent pharmacotherapeutic advances in the treatment of depression have included the development of selective serotonin reuptake inhibitors (SSRIs), thereby providing an alternative to tricyclic antidepressants (TCAs). Herein, we review the pharmacoeconomic literature relative to antidepressant pharmacotherapy and identify issues for future inquiry.
π SIMILAR VOLUMES
This review assesses the evidence regarding the use of long-acting β€ 2 -agonists in the management of pediatric asthma. Thirty double-blind, randomized, controlled trials on the effects of formoterol and salmeterol on lung function in asthmatic children were identified. Single doses of inhaled salm
Evidence-based methodology is enjoying a surge in popularity, but what are the consequences of its rapid acceptance? With contributions from authors associated with the prestigious Cochrane and Campbell collaborations, this state-of-the-art review is essential reading for everyone who uses evidence